News|Videos|June 19, 2024
Empowering Patients With Myeloma Through Resources
The panel discussed resources to equip nurses in educating patients with multiple myeloma about their treatment options.
Advertisement
Episodes in this series
Advertisement
Related to this article
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Breast Cancer Awareness: An APN on Personalized Care and Survivorship
2
Oral Vitamin C Misses Primary End Point in CCUS but Shows Survival Signal
3
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
4
Understanding Opdivo Qvantig® (nivolumab and hyaluronidase-nvhy): A Cancer Treatment with A Faster Delivery*
5